AstraZeneca (NASDAQ:AZN - Get Free Report) was downgraded by stock analysts at Deutsche Bank Aktiengesellschaft from a "hold" rating to a "sell" rating in a research report issued on Thursday,Finviz reports.
Several other equities research analysts have also issued reports on AZN. Weiss Ratings reissued a "buy (b)" rating on shares of AstraZeneca in a research note on Wednesday, October 8th. Berenberg Bank set a $97.00 price objective on AstraZeneca in a research note on Wednesday, July 9th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $86.00.
View Our Latest Analysis on AstraZeneca
AstraZeneca Price Performance
AstraZeneca stock opened at $84.83 on Thursday. AstraZeneca has a one year low of $61.24 and a one year high of $86.57. The business has a fifty day moving average price of $79.82 and a 200-day moving average price of $73.69. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.86 and a quick ratio of 0.67. The firm has a market capitalization of $263.09 billion, a P/E ratio of 31.89, a PEG ratio of 1.56 and a beta of 0.36.
AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $1.09 EPS for the quarter, hitting analysts' consensus estimates of $1.09. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The firm had revenue of $14.46 billion during the quarter, compared to analyst estimates of $14.08 billion. During the same period last year, the company earned $1.24 earnings per share. The business's revenue for the quarter was up 16.1% on a year-over-year basis. As a group, equities research analysts forecast that AstraZeneca will post 4.51 EPS for the current year.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the stock. SCS Capital Management LLC purchased a new position in shares of AstraZeneca in the first quarter worth about $3,066,000. Robbins Farley bought a new stake in shares of AstraZeneca in the second quarter worth about $1,857,000. Oliver Luxxe Assets LLC grew its stake in shares of AstraZeneca by 6.0% in the second quarter. Oliver Luxxe Assets LLC now owns 78,301 shares of the company's stock worth $5,472,000 after purchasing an additional 4,449 shares during the last quarter. Alhambra Investment Management LLC bought a new stake in shares of AstraZeneca in the second quarter worth about $320,000. Finally, Community Trust & Investment Co. grew its stake in shares of AstraZeneca by 21.2% in the second quarter. Community Trust & Investment Co. now owns 226,161 shares of the company's stock worth $15,804,000 after purchasing an additional 39,488 shares during the last quarter. Hedge funds and other institutional investors own 20.35% of the company's stock.
About AstraZeneca
(
Get Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.